The global cancer vaccines market size was worth USD 4.6 billion in 2020 and is estimated to reach USD 10.1 billion by the end of 2025, with a CAGR of 17.28% between 2020 to 2025.
Vaccines were mostly used to prevent contagious diseases; they work by improving the immune response against pathogens. Similarly, cancer vaccines work by activating the immune system to attack cancer cells. Researchers developed therapeutic cancer vaccines to alleviate patients suffering from cancer. With the new technological advances, cancer vaccines have been developed as a new therapeutic way for cancer prevention and eradication. Broad ranges of therapeutics are currently available in the market to effectively combat cancer, but they suffer from many glitches like low effectiveness and high specificity.
The factor which is significantly boosting the growth of the global cancer vaccines market is the rise in the prevalence of HPV infections. The influx of novel cancer vaccines into the market contributes to developing the global cancer vaccines market. The increase in demand for preventive vaccines among people owing to increased awareness of the infectious disease is catalyzing the growth of the cancer vaccines market. Also, increased investments by governments and private organizations for the production of cancer vaccines and the development of alternative therapies due to a consistently rising account of cancer contribute to the growth of the global cancer vaccines market.
Steadily increasing demand and adoption rates of therapeutic and preventive vaccines are expected to create lucrative growth opportunities for key market players in the global cancer vaccines market during the outlook period. Emerging economies of the developing nations such as China and India leading to expansion and technological advancement of healthcare and is likely to offer many growth opportunities for the stakeholders operating in the worldwide cancer vaccines market. Increased focus of medical professionals on research and development of alternative therapies and treatments owing to the continually growing prevalence of cancer at an exponential rate is likely to provide lucrative growth opportunities for the key players functioning in the cancer vaccines market during the projection period.
Stringent regulations and time-taking approval procedures of the FDA, restricting or delaying the launch of newly developed vaccines into the market, are a challenge to the key players and stakeholders, eventually limiting the growth of the cancer vaccines market. Side effects associated with the available therapies are challenging the development of the global cancer vaccines market.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Cancer Type, Vaccine Type, End Users and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Dendreon, GlaxoSmithKline, Merck, Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, OncoThyreon, Oncovir, Oxford BioMedica, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen and Vaxon Biotech |
This research report on the global cancer vaccines market has been segmented and sub-segmented based on the cancer type, vaccine type, end-users, and region.
Cancer Vaccines Market - By Cancer Type:
Cancer Vaccines Market - By Vaccine Type:
Cancer Vaccines Market - By End User:
Based on end-users, the Cancer Treatment Centers contribute the largest share of revenues to the global cancer vaccines market. They are likely to continue the trend over the estimated period owing to the huge patient pool.
Cancer Vaccines Market - By Region:
Geographically, North America is predicted to account for the largest share in the global cancer vaccines market due to increased cancer deaths. The government's escalating awareness about cancer by the government grows the patient’s treatment. The Asia Pacific is expected to show the highest growth due to increased healthcare expenditure in developing countries in this region.
KEY MARKET PLAYERS:
Companies that are playing a leading role in the global cancer vaccines market profiled in the report are Dendreon, GlaxoSmithKline, Merck, Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, OncoThyreon, Oncovir, Oxford BioMedica, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen and Vaxon Biotech.
KEY HAPPENINGS IN THIS MARKET IN THE RECENT PAST:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology Data
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment type
5.1.1 Prophylactic
5.1.2 Therapeutic
5.1.3 Y-o-Y Growth Analysis, By Cancer Type
5.1.4 Market Attractiveness Analysis, By Cancer type
5.1.5 Market Share Analysis, By Cancer Type
5.2 Cancer Type
5.2.1 Introduction
5.2.2 Prostate Cancer
5.2.3 Cervical Cancer
5.2.4 Colorectal Cancer
5.2.5 Throat Cancer
5.2.6 Others
5.2.7 Y-o-Y Growth Analysis, By Cancer Type
5.2.8 Market Attractiveness Analysis, By Cancer type
5.2.9 Market Share Analysis, By Cancer Type
5.3 Vaccine Type
5.3.1 Introduction
5.3.2 Tumour cell Vaccines
5.3.3 Protein or Peptide Vaccines
5.3.4 Genetic Vaccines
5.3.5 Dendritic cell Vaccines
5.3.6 other Vaccines
5.3.7 Y-o-Y Growth Analysis, By Vaccine Type
5.3.8 Market Attractiveness Analysis, By Vaccine Type
5.3.9 Market Share Analysis, By Vaccine Type
5.4 End Users
5.4.1 Introduction
5.4.2 Cancer Treatment Centers
5.4.3 Research Institutes
5.4.4 Y-o-Y Growth Analysis, By End User
5.4.5 Market Attractiveness Analysis, By End User
5.4.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.4 Market Attractiveness Analysis
6.1.5 Market Share Analysis
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Merck & co
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Dendreon
8.3 Glaxosmithkline
8.4 AstraZeneca plc
8.5 Aduro BioTech
8.6 MedImmune
8.7 Sanofi
8.8 Galena Biopharma
8.9 Ubivac
8.10 Oxford Biomedica
8.11 Immunofrontier Inc
8.12 Oncovir Inc
8.13 Immune Cell Therapy (ICT)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
